26-Jun-2023
Cholesterol-Lowering Program Update
26-May-2023
Cholesterol-Lowering Program Preclinical Studies Completed
11-Apr-2023
Cholesterol-Lowering Program Preclinical Development Update
10-Oct-2022
Efficacy Study Published in Journal of Lipid Research
20-Jul-2022
Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis
29-Jun-2022
Cholesterol-Lowering Program Update
17-May-2022
European Patent to be Granted for Cholesterol-Lowering Drug
22-Dec-2021
Cholesterol-Lowering Program Pathway to Phase I
13-Aug-2021
NYX-PCSK9i In Vivo Study Exploratory Analysis Results
30-Jul-2021
Nyrada Announces US Patent Grant for PCSK9 Inhibitor
29-Jun-2021
NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction
5-May-2021
NYR Announces New Potent Cholesterol-Lowering Candidates
25-Jan-2021
Nyrada Reports Further Results from Cholesterol Study
21-Dec-2020
57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study
6-Jul-2020
Nyrada Cholesterol-Lowering Drug Study Results
11-Feb-2020
Significant advance in Nyrada PCSK9i program published